Research Reports

Key takeaways

GAAP revenue for FY2025 was $5.1M, down 52.8% year-over-year, primarily driven by the sale of the Genie® product line during the fiscal year.

GAAP gross profit fell 72.5% year-over-year to $1.3M for FY2025, resulting in a gross margin of 25.8% for the period.

FY2025 GAAP operating loss widened 18.9% year-over-year to $7.9M, as investments in the Bioprocessing Systems segment outpaced current revenue generation.

FY2025 GAAP net loss narrowed 81.1% year-over-year to $1.2M, supported by a gain on the Genie® product line sale and reduced operating expenses.

Diluted GAAP EPS improved 82.0% year-over-year to -$0.11 for FY2025, aligned with the period’s narrower net loss.

Selling expenses decreased year-over-year in FY2025, driven by cost savings initiatives implemented across the Bioprocessing Systems Operations.

Full analysis

Genie® Product Line Divestiture Impacts Fiscal 2025 Topline and Profitability

The sale of the Genie® product line during 2025 was the defining driver of the year’s financial results, per management discussion in Item 7 of this 10-K. The divestiture directly contributed to the 52.8% year-over-year decline in total revenue, while a gain associated with the transaction, paired with reduced operating expenses, drove the 81.1% year-over-year improvement in net loss for the period. The reduction in net loss also translated to an 82.0% year-over-year improvement in diluted earnings per share for fiscal 2025.

SCND · Scientific Industries, Inc.

Summary

Key takeaways

Full analysis

Genie® Product Line Divestiture Impacts Fiscal 2025 Topline and Profitability

Bioprocessing Segment Investment Drives Operating Performance Trends

Going Concern and Forward-Looking Operating Outlook